Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Armata Pharmaceuticals Inc (ARMP) on August 19 and set a price target of $9. The company’s shares closed last Monday at $4.40, close to its 52-week low of $2.15.
According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -11.6% and a 30.0% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Achieve Life Sciences Inc, and Palatin Technologies Inc.
Armata Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $8, a 93.8% upside from current levels. In a report issued on August 15, H.C. Wainwright also maintained a Buy rating on the stock with a $7 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.18 and a one-year low of $2.15. Currently, Armata Pharmaceuticals Inc has an average volume of 61.82K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.
